How do the 9.67 million warrants and 6.37 million stock options outstanding as of September 30, 2025, impact NRGV's future dilution?
Why did NRGV's Board approve a 2025 Inducement Plan in February 2025, reserving 8.0 million shares for new employees?
Why has there been no significant insider buying activity reported despite the recent NYSE compliance on September 3, 2025?
© 2015-2026 Fintel Ventures LLC. All rights reserved. Fintel® is a registered trademark.
This website is provided “as is” without any representations or warranties, express or implied. Fintel makes no representations or warranties in relation to this website or the information and materials provided on this website. Nothing on this website constitutes, or is meant to constitute, advice of any kind. If you require advice in relation to any financial matter you should consult an appropriate professional.
